Cardenas, F.I.; Mauguen, A.; Cheung, I.Y.; Kramer, K.; Kushner, B.H.; Ragupathi, G.; Cheung, N.-K.V.; Modak, S.
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers 2021, 13, 6265.
https://doi.org/10.3390/cancers13246265
AMA Style
Cardenas FI, Mauguen A, Cheung IY, Kramer K, Kushner BH, Ragupathi G, Cheung N-KV, Modak S.
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers. 2021; 13(24):6265.
https://doi.org/10.3390/cancers13246265
Chicago/Turabian Style
Cardenas, Fiorella Iglesias, Audrey Mauguen, Irene Y. Cheung, Kim Kramer, Brian H. Kushner, Govind Ragupathi, Nai-Kong V. Cheung, and Shakeel Modak.
2021. "Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma" Cancers 13, no. 24: 6265.
https://doi.org/10.3390/cancers13246265
APA Style
Cardenas, F. I., Mauguen, A., Cheung, I. Y., Kramer, K., Kushner, B. H., Ragupathi, G., Cheung, N. -K. V., & Modak, S.
(2021). Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers, 13(24), 6265.
https://doi.org/10.3390/cancers13246265